Veterinary Medicines

OVIVAC P PLUS

Authorised
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
  • Bibersteinia trehalosi, serotype T3, Inactivated
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
  • Clostridium tetani, strain 51123/91, toxoid
  • Clostridium septicum, strain s1110/85, toxoid
  • Clostridium perfringens, type D, strain 603, epsilon toxoid
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
  • Mannheimia haemolytica, serotype A7, Inactivated
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
Download as PDF

Product identification

Medicine name:
OVIVAC P PLUS
Active substance:
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
  • Bibersteinia trehalosi, serotype T3, Inactivated
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
  • Clostridium tetani, strain 51123/91, toxoid
  • Clostridium septicum, strain s1110/85, toxoid
  • Clostridium perfringens, type D, strain 603, epsilon toxoid
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
  • Mannheimia haemolytica, serotype A7, Inactivated
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
Target species:
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Bibersteinia trehalosi, serotype T3, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Clostridium tetani, strain 51123/91, toxoid
    2.50
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium septicum, strain s1110/85, toxoid
    2.50
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type D, strain 603, epsilon toxoid
    5.00
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
    0.50
    Protective Dose
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
    0.50
    Protective Dose
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
    0.50
    Protective Dose
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
    0.50
    Protective Dose
    /
    1.00
    millilitre(s)
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Mannheimia haemolytica, serotype A7, Inactivated
    50000000.00
    cells
    /
    0.10
    millilitre(s)
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
    0.50
    Protective Dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Sheep
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI04AB05
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • Carton with one LDPE bottle containing 500 ml (250 doses), closed with a combination cap ofaluminium fitted with a rubber disc or rubber stopper.
  • Carton with one LDPE bottle containing 100 ml (50 doses), closed with a combination cap ofaluminium fitted with a rubber disc or rubber stopper.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet (Ireland) Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10996/149/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 27/07/2025
Download